Furthermore, there is evidence suggesting that androgen blockade with ARPIs leads to a PSMA upregulation in mCRPC, specifically [30, 31], which might allow a synergistic tumor control in combination with PSMA RLT. The gene discussed is FOLH1; the disease is neoplasm.